Literature DB >> 17124045

Thrombosis in infants and children.

Reinhard Schneppenheim1, Jeanette Greiner.   

Abstract

During the last decade much progress has been made toward better understanding of the underlying reasons causing thromboembolism in children. A considerable number of acquired and hereditary thrombotic risk factors have been identified which may also have an impact on therapeutic decisions and prognosis concerning outcome and the risk of a second event. However, indications for therapeutic interventions, such as thrombolysis and prophylactic anticoagulation with respect to the different clinical conditions and their combination with other risk factors, are not yet well defined. The following article describes the causes, clinical presentation and management of thrombosis in neonates, infants and older children, focusing on the clinically most relevant conditions.

Entities:  

Mesh:

Year:  2006        PMID: 17124045     DOI: 10.1182/asheducation-2006.1.86

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  6 in total

1.  Bivalirudin use in an infant with persistent clotting on unfractionated heparin.

Authors:  Katherine M Malloy; Tara A McCabe; Robert J Kuhn
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 2.  Activated protein C action in inflammation.

Authors:  Pranita P Sarangi; Hyun-wook Lee; Minsoo Kim
Journal:  Br J Haematol       Date:  2009-12-08       Impact factor: 6.998

3.  Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients.

Authors:  Sarah E Leary; Virginia L Harrod; Pedro A de Alarcon; Ulrike M Reiss
Journal:  J Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.289

4.  Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis.

Authors:  Lakshmi Venkateswaran; Fernando Scaglia; Valerie McLin; Paula Hertel; Oleg A Shchelochkov; Saul Karpen; Donald Mahoney; Donald L Yee
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

5.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 6.  Thromboembolic complications in children with COVID-19 and MIS-C: A narrative review.

Authors:  Sandra Trapani; Chiara Rubino; Donatella Lasagni; Francesco Pegoraro; Massimo Resti; Gabriele Simonini; Giuseppe Indolfi
Journal:  Front Pediatr       Date:  2022-08-11       Impact factor: 3.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.